Find information on thousands of medical conditions and prescription drugs.

Detrol

Tolterodine (ATC code: G04BD) is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade name Detrol. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective. Tolterodine, however, although it acts on two types of receptors, has less side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are less side effects eg. hyposalivation, constipation, decreased gastric motility.

Read more at Wikipedia.org


[List your site here Free!]


ACOG guidelines on urinary incontinence in women
From American Family Physician, 7/1/05 by Carrie A. Morantz

The American College of Obstetricians and Gynecologists (ACOG) has released recommendations on the diagnosis and treatment of urinary incontinence in women. ACOG Practice Bulletin No. 63 was published in the June 2005 issue of Obstetrics and Gynecology.

Urinary incontinence affects up to 70 percent of community-dwelling women and up to 50 percent of nursing home residents. Prevalence increases gradually during young adulthood, peaks broadly around middle age, then steadily increases in the elderly. In up to 75 percent of ambulatory women with incontinence, urodynamic stress incontinence is the main condition. Most women with incontinence do not seek medical help.

Common causes of urinary incontinence include urinary tract infections; urethritis; atrophic urethritis or vaginitis; pregnancy; increased urine production from hyperglycemia, hypercalcemia, excess fluid intake, or volume overload; delirium; restricted mobility; stool impaction; and psychologic causes. The differential diagnosis includes filling and storage disorders; fistulas; congenital conditions such as ectopic ureters and epispadias; and neurologic, cognitive, psychologic, physical, pharmacologic, and metabolic conditions. Some conditions that cause or contribute to urinary incontinence are potentially reversible.

Diagnosis

The loss of small amounts of urine in spurts during coughing and in the absence of urge strongly suggests a diagnosis of urodynamic stress incontinence. Prolonged loss of urine (i.e., leaking five to 10 seconds after coughing) or no urine loss with provocation may indicate other causes of incontinence, especially detrusor overactivity. The inability to demonstrate the sign of stress incontinence during simple bladder filling and cough stress testing correlates with the absence of urodynamic stress incontinence. However, interpretation of these tests can be difficult. To maximize diagnostic accuracy, tests in patients with borderline or negative results should be repeated.

Even under the most typical clinical situations, the diagnosis of incontinence based only on clinical evaluation may be uncertain. This uncertainty may be acceptable if medical or behavioral treatment, as opposed to surgery, is planned because of the low rate of morbidity and cost of these treatments and because the ramifications of continued incontinence are not severe. When surgical treatment of stress incontinence is planned, urodynamic testing often is recommended to confirm the diagnosis unless the patient has an uncomplicated history and compatible physical findings of stress incontinence and has not had previous surgery for incontinence.

Cystometric testing is indicated as part of the evaluation of more complex disorders of bladder filling and voiding, such as the presence of neurologic disease and other comorbid conditions, but there are only limited data suggesting its need in the routine evaluation of women with urinary incontinence. Multichannel or subtracted cystometry allows more precise measurements of detrusor pressures with filling and voiding, although both false-negative and false-positive results routinely are found with cystometry. No studies have determined whether the addition of multichannel cystometry or video assessment over simple filling cystometry improves diagnostic accuracy or outcomes after treatment. Other complex urodynamic tests, such as pressure-flow voiding studies, uroflometry, and electromyography of the urethral sphincter, are available for the assessment of complex and neurogenic causes of urinary incontinence and voiding disorders.

Cystoscopy is indicated for the evaluation of patients with incontinence who also have hematuria or pyuria; irritative voiding symptoms such as frequency, urgency, and urge incontinence in the absence of reversible causes; bladder pain; recurrent cystitis; suburethral mass; and when urodynamic testing fails to duplicate symptoms of urinary incontinence. Bladder lesions are found in less than 2 percent of patients with incontinence; therefore, cystoscopy should not be performed routinely in patients with incontinence to exclude neoplasm.

Urethral pressure profilometry is not standardized, reproducible, or able to contribute to the differential diagnosis in women with stress incontinence symptoms, and therefore does not meet the criteria for a useful diagnostic test. Leak point pressure measures the amount of increase in intra-abdominal pressure that causes stress incontinence, although its usefulness also has not been proved.

Treatment

A substantial percentage of women who are thought to have detrusor overactivity can be expected to respond to appropriate medical or behavioral therapy. Even women with mixed disorders (i.e., coexistent stress and urge incontinence) respond to various forms of conservative therapy.

PESSARIES

Pessaries and other mechanical devices modified to selectively support the bladder neck may be effective for treating some patients with urinary incontinence, but there is no objective evidence of their effectiveness. Replacement of the prolapsed anterior vaginal wall with a pessary may unmask incontinence by straightening out the urethrovesical kinking that may have been responsible for continence or some degree of urinary retention.

BEHAVIORAL THERAPY

Behavioral therapy improves symptoms of urge and mixed incontinence and is recommended as a noninvasive treatment in many women. Behavioral therapy that includes group and individual instruction, individualized scheduled voiding, diary keeping, and instructions on pelvic muscle exercises may reduce the mean number of incontinence episodes by as much as 50 percent. Data show that behavioral training with biofeedback results in a 63 percent mean reduction in incontinence episodes, compared with a 69 percent mean reduction following verbal feedback and a 59 percent mean reduction after receiving a self-help booklet. For patients with stress incontinence, behavioral training reduced the mean number of incontinence episodes by 69 percent.

Combining drug and behavioral therapy in a stepped program can produce added benefit for patients with urge incontinence. However, there is not enough evidence to show whether drug therapy is better than bladder training or as useful as a supplement.

Obesity may be an independent risk factor for the development of incontinence, with obese women having a 4.2-fold greater risk of stress urinary incontinence than women with normal body mass indices. However, few published studies have addressed the effects of weight loss on incontinence, and those that have addressed this issue only examined the effects of massive weight loss in morbidly obese women.

Pelvic floor training appears to be an effective treatment in adult women with stress and mixed incontinence, and pelvic muscle exercises appear to be better than no treatment or placebo. Pelvic floor exercise reduces incontinence and increases vaginal pressure measurements, but direct correlations between these changes are weak. Pelvic muscle exercise appears to be superior to electric stimulation and vaginal cones in the treatment of stress incontinence. Generally, the effect of adding pelvic muscle training to other treatments for stress incontinence and the effects of pelvic muscle exercise on urge incontinence alone remain unclear.

PHARMACOTHERAPY

Combined hormone therapy and unopposed estrogen therapy have been found to increase the incidence of urinary incontinence in women without symptoms at baseline. In initially symptomatic women, urinary frequency increased with both treatments. Smaller studies examining the use of oral estrogen preparations in the treatment of stress or urge incontinence found that the use of estrogen did not reduce incontinence. Therefore, oral estrogen therapy is not recommended for treatment or prevention of any type of urinary incontinence.

The anticholinergic drugs oxybutynin chloride (Ditropan) and tolterodine (Detrol) may have a small beneficial effect in women with urge incontinence. However, the observed differences between treatment with anticholinergics and placebo may be of questionable clinical significance. The most typical side effect of anticholinergics is dry mouth; other side effects include blurred vision, constipation, nausea, dizziness, and headache.

In women with extensive comorbidity that precludes surgery or anesthesia, injection of bulking agents may be a useful option for relief of symptoms for up to 12 months. Multiple injections may be required to achieve a satisfactory result.

SURGERY

Surgery is indicated for the treatment of stress incontinence when conservative treatments have failed to relieve symptoms satisfactorily and when the patient wishes further treatment in an effort to achieve continence. Although retaining fertility potential is not a contraindication, surgery is a better option if the patient does not wish to have more children.

Not all patients with urinary incontinence need urodynamic testing before surgery. These patients include nonpregnant women who lose urine only with physical exertion and those who have normal voiding habits (i.e., fewer than eight voiding episodes per day and fewer than two per night); no associated neurologic or physical findings; no history of anti-incontinence or radical pelvic surgery; a hypermobile urethra, pliable vaginal wall, and adequate vaginal capacity on physical examination; and a normal postvoid residual volume.

Retropubic colposuspension procedures are indicated for women with urodynamic stress incontinence and a hypermobile proximal urethra and bladder neck. Selection of a retropubic approach (versus a sling) depends on factors such as the need for laparotomy for other pelvic disease, the amount of pelvic organ prolapse, the age and health status of the patient, and whether a vaginal or abdominal procedure will be used to suspend the vagina. Retropubic procedures can be used for intrinsic sphincter deficiency with urethral hypermobility, but sling operations may yield better long-term results. Hysterectomy adds little to the efficacy of Burch colposuspension in curing stress incontinence and should be performed only in patients with specific uterine pathology or uterine prolapse.

One consensus panel review indicated that after 48 months, retropubic suspensions and sling procedures may be more effective than transvaginal needle suspension procedures or anterior colporrhaphy. Retropubic suspensions and sling procedures are associated with slightly higher complication rates, including longer convalescence and postoperative voiding dysfunction.

Long-term data suggest that Burch colposuspension and sling procedures have similar objective cure rates; therefore, treatment selection should be based on patient characteristics and physician experience. Tension-free vaginal tape and open Burch colposuspension have similar success rates.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Detrol
Home Contact Resources Exchange Links ebay